Compare
UFP Technologies Inc vs Bioventus Inc. vs NovoCure Ltd vs Glaukos Corp
| Latest fiscal year | UFP Technologies Inc UFPT | Bioventus Inc. BVS | NovoCure Ltd NVCR | Glaukos Corp GKOS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $602.80M | $568.09M | $655.35M | $507.44M |
| Revenue growth (YoY) | +19.5% | -0.9% | +8.3% | +32.3% |
| Gross margin | 28.3% | 68.3% | 74.5% | 55.7% |
| Operating margin | 15.3% | 9.5% | -23.5% | -39.3% |
| Net margin | 11.3% | 4.0% | -20.8% | -37.0% |
| Net income | $68.31M | $22.73M | -$136.23M | -$187.69M |
| EPS (Diluted) | $8.75 | $0.33 | -$1.22 | -$3.28 |
| Operating cash flow | $91.91M | $74.67M | -$49.03M | -$14.79M |
| Free cash flow | n/a | $72.11M | -$75.68M | -$22.45M |
| Cash & equivalents | $20.30M | $51.24M | $93.55M | $90.81M |
| Total assets | $655.08M | $683.56M | $804.33M | $893.49M |
| Total liabilities | $231.20M | $455.11M | $463.86M | $237.33M |
| Shareholders' equity | $423.88M | $184.10M | $340.47M | $656.15M |
| Return on year-end equity | 16.1% | 12.3% | -40.0% | -28.6% |
| Shares outstanding | 7.71M | n/a | 112.49M | 57.51M |
Revenue, most recent five fiscal years
| Fiscal year | UFP Technologies Inc | Bioventus Inc. | NovoCure Ltd | Glaukos Corp |
|---|---|---|---|---|
| Latest | $602.80M Ended 2025-12-31 | $568.09M Ended 2025-12-31 | $655.35M Ended 2025-12-31 | $507.44M Ended 2025-12-31 |
| 1 year earlier | $504.42M Ended 2024-12-31 | $573.28M Ended 2024-12-31 | $605.22M Ended 2024-12-31 | $383.48M Ended 2024-12-31 |
| 2 years earlier | $400.07M Ended 2023-12-31 | $512.35M Ended 2023-12-31 | $509.34M Ended 2023-12-31 | $314.71M Ended 2023-12-31 |
| 3 years earlier | $353.79M Ended 2022-12-31 | $512.12M Ended 2022-12-31 | $537.84M Ended 2022-12-31 | $282.86M Ended 2022-12-31 |
| 4 years earlier | $206.32M Ended 2021-12-31 | $430.90M Ended 2021-12-31 | $535.03M Ended 2021-12-31 | $294.01M Ended 2021-12-31 |